TUCSON   520.748.4400

Therapeutic Human Polyclonals, Inc.

Therapeutic Human Polyclonals, Inc., (THP) was founded as a biotherapeutics company to develop a unique transgenic mammalian platform to create human antibodies. THP was the first company to create transgenic rabbits with a human antibody repertoire for producing both monoclonal and polyclonal antibody therapeutics.

Roche, the world’s largest biotechnology company, completed its acquisition of THP for $56.5 million in March 29, 2007.